Tag Archives: stage II colon cancer

Calling All Stage II Men Survivors!

Have you been diagnosed with stage II colon cancer? We need a few more men to complete a 30 minute survey to help inform a study focused on patients like you. If you were diagnosed with stage II colon cancer any time since 2010, researchers from the University of California-Los Angeles and the University of Pittsburgh would like to talk with you. These researchers have asked Fight Colorectal Cancer for assistance in finding colon cancer survivors who can help them design a survey for use in a study about how stage II colon cancer patients make decisions about treatment. Participation would involve: Scheduling a one-time, 30-minute phone call with the

Highlights from ASCO 2011

While there weren’t new blockbuster announcements for colorectal cancer this year at the American Society for Clinical Oncology’s (ASCO) Annual Meeting, there was plenty of focus on making what we already have work better and on choosing the patients who will benefit the most from treatments, as well as those who might not be helped at all. (Note, many of these issues will be discussed in detail on our upcoming patient webinar.) Highlights: While adding oxaliplatin to 5-FU improves five year survival slightly for stage II colon cancer, it increases side effects, particularly tingling and numbness in the feet.  An analysis of several NSABP trials found that two or three

Chemo Delay After Surgery Reduces Survival Rates

A paper presented at the recent 2011 Gastrointestinal Cancers Symposium conference reported important evidence that, for colorectal cancer patients getting chemotherapy after surgery, the sooner the better. For people diagnosed with stage III colon cancer, stage II rectal cancer, or stage II colon cancer showing certain high-risk features, researchers found that each four-week delay in starting chemotherapy after surgery was associated with a 12% lower rate of survival five years later.

Leading GI Cancer Researcher Updates Patients

Last night, Dr. Edith Mitchell of Thomas Jefferson University Kimmel Cancer Center in Philadelphia, PA, updated colorectal cancer patients on the latest research and treatment news in an online webinar. Dr. Mitchell highlighted the most important news for colon and rectal cancer patients to come from the 2011 Gastrointestinal Cancers Symposium held in San Francisco last month. She answer such questions as… “Can doctors determine the chances that my cancer may return?” “Can my doctors determine if I need chemotherapy?” “Does Avastin or Erbitux benefit my stage III cancer treatment?” “Are there any promising new treatments on the horizon?”

New GeneTest Guides Stage II Colon Cancer Risk

Most patients with stage II colon cancer will be fine after surgery, with little risk that their cancer will come back. But one in five will have cancer spread beyond their colon. Better information about which patients will relapse could spare many from the risks of chemotherapy. A new gene test announced at the 2011 Gastrointestinal Cancer Symposium in San Francisco helps provide answers to which patients are at highest risk and could help patients and their doctors make better decisions about follow-up chemotherapy after surgery. ColoPrint, an 18 gene tumor tissue signature, found that three out of four patients with stage II colon cancer had only about a 5

DNA Mismatch Repair and 5-FU: What's the Connection?

Some colon cancer patients don’t benefit from treatment with 5-FU based chemotherapy and may even have worse outcomes than if they no chemo at all. Of every 100 people with colon cancer, about 15 will have cancers that arise when mistakes in DNA during cell division are not caught and fixed.  Scientists call this defective mismatch repair or dMMR. More often, colon cancer occurs when mutations in chromosomes accumulate but DNA repair pathways remain intact and mismatch repair is proficient (pMMR). This is true for about 85 percent of colon cancer. Both prognosis and the potential benefit from FU-based chemotherapy appear to be very different for these two types of

No Difference in Chemotherapy Benefits for Young Patients with Stage II and III Colon Cancer Compared to Those Fifty and Older

Young patients with stage II or III colon cancer get equal benefit from chemotherapy as older patients, and they have similar side effects. Five years after treatment, 67 percent of patients under the age of fifty hadn’t had their cancer spread beyond the colon (recurrence-free interval), the same percentage that applied to patients who were fifty or over. Overall survival and disease-free survival were somewhat better for young patients because they had fewer other reasons for dying.  Overall and disease-free survival reflect patients who are alive five years after beginning treatment.  Neither includes people who have died from any cause, including their cancer.

Stage II Recurrence Test Now Available

How likely is it that an individual colon cancer will return? Stage II colon cancer patients have a tough time knowing how likely it is that their cancer will recur and making a decision about having chemotherapy after surgery. A test is now on the market that can help with that decision.  OncoType DX® Colon Assay analyzes 12 key genes from a tumor sample to produce a recurrence score that indicates how likely stage II colon cancer will return. While OncoType DX Colon can’t predict whether chemotherapy will reduce the chance that cancer will come back, it can help patients and their doctors decide on chemotherapy in combination with other

ASCO Research Highlights: Molecular Markers in Stage II and III Colon Cancer

Several studies presented at ASCO looked a biomarkers that might predict cancer recurrence or patient survival in stage II and III colon cancer and whether patients could be chosen to receive chemotherapy based on those markers.  Of special interest was the hypothesis offered by two researchers from the PETACC-3 clinical trial that stage II and stage III may be very different biologically.  As Dr. Arnaud Roth said, “. . .in other words, could be different diseases.”

Gene Test Shows Risk of Recurrence of Stage II Colon Cancer

The first genomic test to predict whether or not stage II colon cancer will recur has been developed and validated in a large number of tumor tissue samples from patients in the United States and the United Kingdom.  The 12 gene assay can reliably predict whether an individual patient has a low, intermediate, or high risk of having their cancer return. Doctors and patients will be able to use the Recurrence Score, along with other clinical indicators, to decide whether further chemotherapy treatment after surgery should be considered or whether they can safely skip chemo and its risks. However, the study was not able to link recurrence scores with benefits